ING Group’s Inovio Pharmaceuticals INO Stock Holding History

ING Group’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-12,156	Closed	-$429K	–	614
2019 Q2	$429K	Hold	12,156	–	–	0.01%	560
2019 Q1	$544K	Buy	12,156 +6,323	+108%	+$319K	0.01%	435
2018 Q4	$280K	Hold	5,833	–	–	0.01%	601
2018 Q3	$389K	Buy	+5,833	New	+$325K	0.01%	592
2018 Q2	–	Sell	-5,833	Closed	-$330K	–	784
2018 Q1	$330K	Hold	5,833	–	–	0.01%	588
2017 Q4	$289K	Hold	5,833	–	–	﹤0.01%	657
2017 Q3	$444K	Buy	5,833 +4,166	+250%	+$310K	0.01%	534
2017 Q2	$157K	Sell	1,667 -5,560	-77%	-$476K	﹤0.01%	805
2017 Q1	$574K	Hold	7,227	–	–	0.01%	423
2016 Q4	$600K	Hold	7,227	–	–	0.01%	402
2016 Q3	$803K	Hold	7,227	–	–	0.01%	315
2016 Q2	$801K	Sell	7,227 -1,666	-19%	-$202K	0.01%	276
2016 Q1	$928K	Sell	8,893 -29,167	-77%	-$2.25M	0.01%	299
2015 Q4	$3.07M	Buy	38,060 +29,135	+326%	+$2.32M	0.02%	365
2015 Q3	$618K	Sell	8,925 -25,302	-74%	-$2.2M	﹤0.01%	490
2015 Q2	$3.35M	Buy	34,227 +32,927	+2,533%	+$3.52M	0.02%	404
2015 Q1	$127K	Buy	+1,300	New	+$126K	﹤0.01%	777

Other funds holding INO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

ING Group's INO Position: Q3 2019 in Review

ING Group sold out of Inovio Pharmaceuticals (INO) in Q3 2019, closing a stake of 12,156 shares — an estimated $429K sold.

ING Group first reported a position in INO in Q1 2015 and held it in 17 quarters. The position peaked at $3.35M in Q2 2015. 118 funds tracked by Wall St. Rank hold INO as of Q3 2019.

ING Group reported no remaining Inovio Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
ING Group sold 12,156 Inovio Pharmaceuticals shares in Q3 2019, an estimated $429K.
ING Group first reported a position in Inovio Pharmaceuticals in Q1 2015 and held it in 17 quarters.
ING Group's Inovio Pharmaceuticals position peaked at $3.35M in Q2 2015.
118 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q3 2019.

Based on ING Group's 13F filing for Q3 2019, filed 8 Nov 2019.